Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Hematology
•
Benign Hematology
•
Von Willebrand
How do you manage bleeding or peri-procedural care for vWD patients whose vWF levels have increased or normalized from age or hormonal contraceptive use?
How do you think about removing the vWD diagnosis if levels have normalized from age?
Related Questions
For von Willebrand type 2B, do you expect a decline in platelet count over time as vWF increases with age?
Is there any benefit to using desmopressin over vWF replacement therapy for vWD?
Do you use direct oral anticoagulants to treat port-a-cath related VTE in patients with an active malignancy?
How is your experience with point-of-care INR systems for home monitoring of vitamin K antagonists?
How quickly do you expect iron stores to decrease after starting iron chelators?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
How do you manage hemophilia A carriers with no history of bleeding complications but with mildly low factor VIII activity (6-40%)?
What would you recommend for long term management of extensive dural venous sinus thrombosis (CVST) in young females when the only provoking risk factor is combined OCP?
How do you decide between HSCT and immunosuppressive therapy for treating hepatitis associated aplastic anemia?